CClinicalTrials.gg
Sign In
WithdrawnNCT00159276Updated Apr 4, 2024

GR Defect in Sputum Cells in COPD

An observational study in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Imperial College London. Withdrawn at 1 site in United Kingdom. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-04-04.

Sponsored by Imperial College London · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
0
Ages
35 Years to 85 Years
Sex
All
01

Study summary

To investigate a possible mechanism of the GR defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR-GRE binding, expression of inflammatory and anti-inflammatory factors such as IL-6, IL-8, MKP-1, GILZ, SLPI production in sputum cells

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
03

In context

Lung Diseases, Obstructive

2,592 studies on the registry are indexed under Lung Diseases, Obstructive; 198 are open to participants now.

Browse Lung Diseases, Obstructive studies →

Lead sponsor

Imperial College London is the lead sponsor of 825 studies on the registry; 179 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All

Inclusion criteria

  • Patients with moderate (stage II, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers.
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Current upper respiratory tract infections
  • Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study
  • Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
0 participants (actual)

Interventions

  • ProcedureInduced Sputum
06

Study locations

1 site
  • Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
    London, SW3 6LY, United Kingdom
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00159276
Lead sponsor
Imperial College London
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Dec 2005 (estimated)
Primary completion
Dec 2005 (estimated)
Completion
Dec 2005 (estimated)
Last update
Apr 4, 2024

Study contacts

Sergei A Kharitonov, MD PhD
principal investigator · Imperial College London
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Diseases, Obstructive→

Other studies from this sponsor

Imperial College London

Start the discussion